Melagatran
This direct thrombin inhibitor was developed to prevent blood clots after orthopedic surgery and was used as the prodrug form of ximelagatran. It was withdrawn from the market due to rare but serious liver toxicity observed during clinical use.
Moleküler Ağırlık
429,5000 g/mol
LogP
-1,00
TPSA
149,00 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Yapı
Cite this structure
Embed this structure
SMILES
N=C(N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](NCC(=O)O)C2CCCCC2)cc1
InChI
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
Molecular Formula
C22H31N5O4
HBD / HBA
5 / 6
Döndürülebilir Bağlar
9
Ağır Atomlar
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This direct thrombin inhibitor was developed to prevent blood clots after orthopedic surgery and was used as the prodrug form of ximelagatran. It was withdrawn from the market due to rare but serious liver toxicity observed during clinical use.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Melagatran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL266349. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 183797. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="melagatran"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/melagatran/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/melagatran/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/melagatran/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="melagatran"></drugfyi-drug>